Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TT-01488 by TransThera Sciences (Nanjing) for Mantle Cell Lymphoma: Likelihood of Approval
TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Mantle Cell Lymphoma. According to...
TT-01488 by TransThera Sciences (Nanjing) for Follicular Lymphoma: Likelihood of Approval
TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Follicular Lymphoma. According to GlobalData,...
TT-01488 by TransThera Sciences (Nanjing) for Marginal Zone B-cell Lymphoma: Likelihood of Approval
TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Marginal Zone B-cell Lymphoma. According...
TT-01488 by TransThera Sciences (Nanjing) for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...
TT-01488 by TransThera Sciences (Nanjing) for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...
TT-01488 by TransThera Sciences (Nanjing) for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...